NTLA:NASDAQ
Intellia Therapeutics Inc
$12.21
arrow_downward
-4.16%(-0.53) 1D
$12.25
arrow_upward
+0.33% (+0.040)bedtimeAfter hours
Closed: Sep 9, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NTLA...
Open
$12.50
High
$12.82
Low
$12.19
Mkt. cap
1.71B
Avg. vol.
3.40M
Volume
0.00
52-wk high
$28.24
52-wk low
$7.95
EPS
-$3.36
Beta
1.82
Shares outstanding
140.13M
No. of employees
377
Open
$12.50
High
$12.82
Low
$12.19
Mkt. cap
1.71B
Avg. vol.
3.40M
Volume
0.00
52-wk high
$28.24
52-wk low
$7.95
EPS
-$3.36
Beta
1.82
Shares outstanding
140.13M
No. of employees
377
News stories
From web sources and news partners
Pluang
·
13 hours ago
Intellia Therapeutics gains as FDA grants Prior...
Zacks
·
14 hours ago
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Quiver Quantitative
·
15 hours ago
Intellia Therapeutics Stock Short Interest Rises to 40.35%
Zacks Investment Research
·
15 hours ago
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websiteintelliatx.com